Hepatitis C virus: here comes all-oral treatment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24591471.
- Also identified by DOI 10.3949/ccjm.81a.13155.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new direct-acting antivirals-sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)-opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development.
Medical subject headings
- Antiviral Agents
- DNA-Directed RNA Polymerases
- Hepatitis C, Chronic
- Heterocyclic Compounds, 3-Ring
- Protease Inhibitors
- Sulfonamides
- Uridine Monophosphate